APA (7th ed.) Citation

E, S. J., A, P. Z., H, C. C., L, R. A., J, G. C., J, B. M., & N, P. Z. (2016). Contribution of infliximab population pharmacokinetic model for dose optimization in ulcerative colitis patients. Revista espanola de enfermedades digestivas, 108(2), 104.

Chicago Style (17th ed.) Citation

E, Santacana Juncosa, Padullés Zamora A, Colom Codina H, Rodríguez Alonso L, Guardiola Capo J, Bas Minguet J, and Padullés Zamora N. "Contribution of Infliximab Population Pharmacokinetic Model for Dose Optimization in Ulcerative Colitis Patients." Revista Espanola De Enfermedades Digestivas 108, no. 2 (2016): 104.

MLA (9th ed.) Citation

E, Santacana Juncosa, et al. "Contribution of Infliximab Population Pharmacokinetic Model for Dose Optimization in Ulcerative Colitis Patients." Revista Espanola De Enfermedades Digestivas, vol. 108, no. 2, 2016, p. 104.